



U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	601-1-134PCTUS
		SERIAL NO.	10/521,841
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT INFORMATION DISCLOSURE STATEMENT		APPLICANT	WIEDER, Robert
		FILING DATE	July 27, 2005
		GROUP	1609

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		TITLE:
	AA	Korah, et al., Integrin $\alpha 5\beta 1$ Promotes Survival of Growth-Arrested Breast Cancer Cells: An <i>in Vitro</i> Paradigm for Breast Cancer Dormancy in Bone Marrow, <i>Cancer Research</i> , 64: 4514-4522 (2004)
	AB	Stoeltzing et al., Inhibition of Integrin $\alpha 5\beta 1$ Function with a Small Peptide (ATN-161) Plus Continuous 5-Fu Infusion Reduces Colorectal Liver Metastases and Improves Survival in Mice, <i>Int. J. Cancer</i> , 104: 496-503 (2003)
	AC	Khalili et al., A Non-RGD-based Integrin Binding Peptide (ATN-161) Blocks Breast Cancer Growth and Metastasis <i>in vivo</i> . <i>Mol. Cancer Ther.</i> , 5:2271-2280 (2006)
	AD	Braun, et al., Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients, <i>J. Clinical Oncology</i> , 18:80-86 (2000)
	AE	Braun, et al., Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II or III Breast Cancer, <i>New England Journal of Medicine</i> , 342: 525-534 (2000)

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.